Daijiro Harada

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

The Role of STAT3 in Non-Small Cell Lung Cancer

Daijiro Harada, Nagio Takigawa, Katsuyuki Kiura · Cancers · 2014 · 191 citations · Full text

Medicine, Cancer Biology, Oncology +16

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki et al. · Journal of Thoracic Oncology · 2017 · 175 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami et al. · Journal of Thoracic Oncology · 2015 · 104 citations

Medicine, Oncology, Pharmacology +12

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Eiji Iwama, Kazuko Sakai, Koichi Azuma et al. · Annals of Oncology · 2016 · 93 citations

Medicine, Molecular Genetics, Oncology +17